key: cord-0797532-vaqiiem3
authors: Murakami, Eric; Ghatak-Roy, Aditi; Popova, Margarita; Gannon, Carin; Park, Daniel E.; Villani, Jack; Liu, Cindy; Toma, Ian; Lafleur, John
title: COVID-19 infection among emergency department healthcare providers in a large tertiary academic medical center following the peak of the pandemic
date: 2020-12-02
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.11.064
sha: b1a7eefda7013b5122933a516503c04fb8d64c12
doc_id: 797532
cord_uid: vaqiiem3

The COVID-19 pandemic has spread through the US during the last few months exposing healthcare providers to possible infection. Here we report testing of emergency department (ED) healthcare providers (HCP) for exposure to COVID-19 through lateral flow point of care (POC) and lab-based enzyme-linked immunosorbent assay (ELISA), and RTq-PCR for evidence of acute infection. 138 ED HCP were tested between May 26th (approximately one month after the peak of COVID-19 first wave of cases) and June 14th. Enrolled ED HCP represented about 70% of the total ED HCP workforce during the study period. Subjects were tested with a POC COVID-19 antibody test, and standard ELISA performed by a university-based research lab. Subjects also provided a mid-turbinate swab and a saliva specimen for RT-PCR. All subjects provided demographic information, past medical history, information about personal protective equipment (PPE) use, COVID-19 symptoms, as well as potential COVID-19 exposures during the previous 4 weeks, both in the ED, and outside the clinical setting. None of the HCP had positive RT-PCR results; 7 HCP (5%) had positive IgG for COVID-19; there was strong agreement between the lab-based ELISA (reference test) and the POC Ab test (P ≤ 0.0001). For the POC Ab test there were no false negatives and only one false positive among the 138 participants. There was no significant difference in demographic/ethnic variables, past medical history, hours worked in the ED, PPE use, or concerning exposures between seropositive and seronegative individuals. Moreover, there was no significant difference in reported symptoms between the two groups during the previous four weeks. The rate of COVID-19 seroconversion in our ED was 5% during the month following the pandemic's first wave. Based on questionnaire responses, differences in demographics/ethnicity, medical history, COVID-19 exposures, and PPE use were not associated with ED HCP having been infected with SARS-CoV-2. In the setting of our limited cohort of subjects the COVID-19 POC Ab test performed comparably to the ELISA lab-based standard.

unrelated to intensity of exposure, 13 other reports highlight the importance of the degree of infection in the community as key to the risk posed to HCPs 14, 15 . One such report, based upon extensive modeling, concludes that infection among US HCPs is about 10 times the rate of documented COVID-19 infection in the community 14 . Assuming 5,800,000 diagnosed US cases at the end of August, 2020-1.8% of the population--that would suggest 18% of frontline HCP in the US had been infected. A recent screening study of HCP in Britain employed serology in addition to RT-PCR, reported 18% infection rate in a large cohort of healthcare workers from two London hospitals, at a time when the estimates of COVID-19 prevalence in the surrounding area was about 0.3% 16 . Antibody testing of ED HCP in an urban hospital in mid-April, 2020 found a COVID-19 prevalence of 5-10% at a time when the incidence of COVID-19 in the surrounding community was 0.1% 17 . While reports of prevalence of COVID-19 among HCP far greater than that of the surrounding community argues strongly for occupational exposure, some recent reports have asserted that occupational exposure in HCP is a minor factor, and COVID-19 among HCP reflect the exposure to the disease in the surrounding community 14, 18 .

To address this question in a single busy, urban emergency department (ED) we undertook to test a high proportion of frontline HCPs during a period of two weeks starting one month following the peak of the pandemic's first wave in Washington, DC. Like the US, to date about 1.8% of the population of Washington, DC has tested positive for COVID-19. We reasoned that a single cohort of HCP equally exposed to COVID-19 would provide a reliable basis for assessing occupational risks of caring for these patients in the emergency setting. To test ED HCP, Multiple different testing modalities were employed including a point of care (POC) lateral flow J o u r n a l P r e -p r o o f antibody test, ELISA serology performed by a university research lab, and two different COVID-19 RT-PCR tests: a mid-turbinate nasal swab and a saliva sample.

The POC antibody test was included as it is a rapid, easy-to-use, free standing testing platform which greatly decreases obstacles to implementation, and thus, if accurate, has the potential to facilitate efficient screening for COVID-19 exposure among groups of frontline HCP, and/or, other groups. Lateral flow POC COVID-19 Ab tests were recently reported to show good positive predictive value in a large scale study of HCP 16 , tracking the performance of ELISA serology reasonable closely.

ED HCP were defined as any ED staff that come into close contact with ED patients while delivering medical care. Roles included in the study were physicians, advanced practice providers, nurses, and technicians. About 200 ED HCP were eligible for inclusion in the study; 

Three samples were collected from each ED HCP. Self-collected mid-turbinate samples were collected using a 3D printed lattice swab (Resolution Medical). Participants were instructed to insert swabs to the mid-turbinate and rotate slowly for 5-10 seconds and repeat for both nostrils. Swabs were collected placed into DNA/RNA Shield (Zymo Research). Participants selfcollected at least 1 mL of saliva into a sterile cup. Venous blood was collected into BD Vacutainer Mononuclear Cell Preparation Tubes containing sodium heparin (Becton Dickinson).

RNA was extracted from a 50 μL aliquot of each specimen using the MagMax-96 Viral RNA Isolation Kit (Thermo Fisher) with a 50 μL elution volume. SARS-CoV-2 genomic RNA was detected using the CDC 2019-nCoV EUA qRT-PCR test (Integrated DNA Technologies). The targets in this panel are two SARS-CoV-2 nucleocapsid genes (N1 and N2) and the human RNAse P gene. The CDC 2019-nCoV EUA test was performed with qScript One-Step qRT-PCR reagents (Quantabio) on a LightCycler 480 Real-Time PCR Instrument (Roche). Cq values were assigned using the maximum second derivative method and a sample was considered positive for SARS-CoV-2 if both the N1 and N2 targets were detected. Performance testing with inactivated SARS-CoV-2 virus (BEI Resources) established the lower limit of detection at 12.5 copies/uL.

Blood samples were spun down at 500 x g at room temperature for 15 minutes with the brake on 1 to separate blood components. Up to 3 mL of plasma from each tube were aliquoted to cryotubes and heat-inactivated for one hour at 56°C prior to analysis. Of the 138 health care workers enrolled, 133 had Nasal swab testing with 4 having insufficient sample, and one specimen not collected; none tested positive for SARS-CoV-2. Saliva specimens were tested with COVID-19 qRT-PCR on 137 individuals with one insufficient specimen--none were found to be positive for SARS-CoV-2.

In the 138 surveyed, 47 (34%) reported at least one symptom suspicious for COVID-19 in the previous 4 weeks (see Table 1 .), with only one seropositive subject reporting symptoms (see Table 3 .). N95 respirator usage was surveyed and no significant J o u r n a l P r e -p r o o f difference between those with positive serology versus those with negative serology (see table   2 .). Powered air-purifying respirator (PAPR) use was 14% among seropositive subjects, versus 31% of those that were seronegative. 54% of study subjects reported having at least one work exposure in the previous 4 weeks without appropriate PPE; no significant difference in unprotected clinical exposures was found between seropositive and seronegative patients.

Similarly, 21 subjects reported at least one unprotected community exposure in the previous 4 weeks without any difference between seropositive and seronegative patients.

To date population-wide assessment of infection with COVID-19 is limited by a combination of factors, including a high proportion of asymptomatic infection, 22 and imperfections in the available tests. Indeed, the production of antibodies against COVID-19 was reported in over 80% of those with moderates to severe COVID-19, but only about 15% of exposed contacts who tested positive via RT-PCR but had mild or asymptomatic infection 23 . What's more, evidence for immunity to COVID-19 has been reported in individuals that otherwise had negative RT-PCR, and serology 24 . This combination of factors has made it impossible to accurately determine population-level prevalence of infection with COVID-19. Be that as it may, serology provides the only practical means available at present for obtaining a longitudinal snapshot of COVID-19 within a given population. And, since positive serology is associated with more severe infection, it also provides information about the vulnerability of that population to clinically significant disease. What serology cannot tell us is the incidence of infection and, by extension, the risk of transmission, over time, within a population.

In those who have antibody responses, they are generally measurable by 3 weeks after symptoms onset; the median time for ongoing viral shedding after seroconversion has been reported as 2 weeks 25 . Since we were testing a cohort of ED HCP about one month to six weeks after the peak of the pandemic's first wave, the combination of RT-PCR for acute disease and serology for resolved COVID-19 infection was considered adequate for evaluating the burden of disease in our subjects. At the time of testing none of the study subjects had ongoing symptoms suggestive of COVID-19, meaning that the likelihood of our missing COVID-19 was low, and, in any case, there is not at present practical means for identifying all COVID-19 infections.

COVID-19 seroconversion in our cohort was 5%. This falls into the range most widely reported for HCP across a broad range of studies 3, 6, [8] [9] [10] [11] 16 . For reasons noted above, the actual incidence of infection in our cohort was probably higher, however, the seroconversion rate allows us to draw comparisons with other populations, similarly studied, and estimate the ongoing risk of significant COVID-19 disease to similar cohorts of HCP going forward. The seroconversion rate in our cohort, like that in most other reports, is higher than that in the surrounding community, supporting the conclusion that for frontline HCP, the risk is mostly occupational. At the time of testing the background prevalence of Covid-19 in our area was estimated at 1.8%. While reported estimates for the risk of Covid-19 in HCPs range as high as ten times the level in the surrounding community 14 , others report that occupational factors accounted for only 27% of the risk for Covid-19 among HCPs. Based upon the prevalence of Covid-19 in our community at the time of testing, 5% positivity among ED HCPs would seem to be accounted for by neither model. Positivity ranging around 5% percent, however, has been reported in many recent studies of Covid 19 among HCPs, as noted above, while at the same time scattered reports of J o u r n a l P r e -p r o o f much higher incidences of Covid-19 among HCPs has also been reported. This suggests that the kinetics of transmission of Covid-19 to HCPs may be a complex phenomenon difficult to predict on the basis of a small number of parameters.

The reported history of COVID-19-like symptoms in our cohort during the weeks prior to testing was not different in those that were seropositive compared to those seronegative. There was also no difference in reported PPE use, or concerning exposures between these two groups.

Taken together one way of interpreting these findings is that with prudent use of PPE and hygienic measures currently employed in our ED and many others, a small number of HCP will become infected as the result of random variation in risk/exposure which are not eliminated by current infection-control practices 26, 27 .

Performance of a lateral flow POC Ab detection device in our study demonstrates that this convenient, inexpensive, easy-to-use device may be deployed to assess COVID-19 seroprevalence within populations of interests with minimal technical obstacles. While not a gold standard for COVID-19 serology, these devices provide some information about the penetrance of the disease within a population, which can be invaluable for comparative and public health purposes 28, 29 . The device used in our study, as was recently reported for another device 16 , performed with little less precision than the lab-based gold-standard ELISA.

Following the Covid-19 pandemics first wave ED HCPs were found to have 5% seropositivity; comparable to similar reports in the literature. In our cohort Covid 19 seropositivity was not predicted by the experience of symptoms during the previous 4 weeks, use of PPE, or subjects' 

Infection and mortality of healthcare workers worldwide from COVID-19: a scoping review

Pan American Health Organization & World Health Organization. Epidemiological Alert: COVID-19 among health workers -31 August 2020 -PAHO/WHO | Pan American Health Organization

COVID-19 among healthcare workers in a specialist infectious diseases setting in Naples, Southern Italy: results of a cross-sectional surveillance study

Effective control of sars-cov-2 transmission between healthcare workers during a period of diminished community prevalence of covid-19

Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers

SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients

Impact of SARS-CoV-2 pandemic among health care workers in a secondary teaching hospital in Spain

COVID-2019) Infection Among Health Care Workers and Implications for Prevention Measures in a Tertiary Hospital in Wuhan, China

Prevalence of Sars-Cov-2 infection in health workers (HWs) and diagnostic test performance: the experience of a teaching hospital in central Italy

Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

Infection with SARS-CoV-2 in primary care health care workers assessed by antibody testing

Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network -13 Academic Medical Centers

Anesthesiologists' and intensive care providers' exposure to COVID-19 infection in a New York City academic center

Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study

Using serological data to understand unobserved SARS-CoV-2 risk in health-care settings

Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study

Prevalence of IgG antibodies to SARS-CoV-2 among emergency department employees

SARS-CoV-2 infection in Health Care Workers

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Index for Rating Diagnostic Tests

Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples

A systematic review of asymptomatic infections with COVID-19

SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2

Translating COVID-19 Pandemic Surge Theory to Practice in the Emergency Department: How to Expand Structure

Bracing the Emergency Department for the COVID-19 Era

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Assessing the extent of SARS-CoV-2 circulation through serological studies